

Jose Maria Portoles Perez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3407727/publications.pdf>

Version: 2024-02-01

95
papers

4,547
citations

218662

26
h-index

102480

66
g-index

102
all docs

102
docs citations

102
times ranked

5159
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidemiology of acute renal failure: A prospective, multicenter, community-based study. <i>Kidney International</i> , 1996, 50, 811-818.	5.2	844
2	Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease. <i>New England Journal of Medicine</i> , 2013, 369, 2492-2503.	27.0	844
3	The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1327-1339.	0.7	491
4	Effect of Membrane Permeability on Survival of Hemodialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 645-654.	6.1	364
5	Cardiovascular effects of recombinant human erythropoietin in predialysis patients. <i>American Journal of Kidney Diseases</i> , 1997, 29, 541-548.	1.9	189
6	Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. <i>Kidney International</i> , 2008, 74, S75-S81.	5.2	137
7	Eculizumab in secondary atypical haemolytic uraemic syndrome. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 466-474.	0.7	121
8	A retrospective study of pregnancy-associated atypical hemolytic uremic syndrome. <i>Kidney International</i> , 2018, 93, 450-459.	5.2	100
9	Peginesatide in Patients with Anemia Undergoing Hemodialysis. <i>New England Journal of Medicine</i> , 2013, 368, 307-319.	27.0	94
10	Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents. <i>Frontiers in Medicine</i> , 2021, 8, 642296.	2.6	91
11	Chronic kidney disease and acute kidney injury in the COVID-19 Spanish outbreak. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1353-1361.	0.7	88
12	Differential effects of the second SARS-CoV-2 mRNA vaccine dose on TÂcell immunity in naive and COVID-19 recovered individuals. <i>Cell Reports</i> , 2021, 36, 109570.	6.4	86
13	Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in Spain: the MERENA observational cohort study. <i>BMC Nephrology</i> , 2011, 12, 53.	1.8	76
14	The development of anemia is associated to poor prognosis in NKF/KDOQI stage 3 chronic kidney disease. <i>BMC Nephrology</i> , 2013, 14, 2.	1.8	69
15	Effect of Different Dialysis Modalities on Microinflammatory Status and Endothelial Damage. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 227-234.	4.5	61
16	A prospective multicentre study of the role of anaemia as a risk factor in haemodialysis patients: the MAR Study. <i>Nephrology Dialysis Transplantation</i> , 2006, 22, 500-507.	0.7	42
17	Baseline characteristics of an incident haemodialysis population in Spain: results from ANSWER—a multicentre, prospective, observational cohort study. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 578-588.	0.7	42
18	Previous Comorbidity and Lack of Patient Free Choice of Technique Predict Early Mortality in Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2009, 29, 150-157.	2.3	41

#	ARTICLE	IF	CITATIONS
19	Microvesicles from indoxyl sulfate-treated endothelial cells induce vascular calcification in vitro. Computational and Structural Biotechnology Journal, 2020, 18, 953-966.	4.1	35
20	FUNCTIONAL GLOMERULAR RESERVE IN RECIPIENTS OF EN BLOC PEDIATRIC TRANSPLANT KIDNEYS. Transplantation, 1998, 65, 677-680.	1.0	35
21	Spanish Society of Nephrology document on KDIGO guidelines for the assessment and treatment of chronic kidney disease. Nefrologia, 2014, 34, 302-16.	0.4	35
22	Markers of endothelial damage in patients with chronic kidney disease on hemodialysis. American Journal of Physiology - Renal Physiology, 2017, 312, F673-F681.	2.7	33
23	DOUBLE RENAL TRANSPLANT FROM INFANT DONORS. Transplantation, 1996, 61, 37-40.	1.0	29
24	Rapid, scalable assessment of SARS-CoV-2 cellular immunity by whole-blood PCR. Nature Biotechnology, 2022, 40, 1680-1689.	17.5	29
25	Mortality in incident haemodialysis patients: time-dependent haemoglobin levels and erythropoiesis-stimulating agent dose are independent predictive factors in the ANSWER study. Nephrology Dialysis Transplantation, 2010, 25, 2702-2710.	0.7	27
26	Rapid decline of anti-SARS-CoV-2 antibodies in patients on haemodialysis: the COVID-FRIAT study. CKJ: Clinical Kidney Journal, 2021, 14, 1835-1844.	2.9	27
27	Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis. Journal of Nephrology, 2003, 16, 697-702.	2.0	27
28	Alveolar Hemorrhage Associated With Antineutrophil Cytoplasmic Antibodies in Rheumatoid Arthritis. Chest, 1994, 105, 1590-1592.	0.8	26
29	Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19. Kidney International Reports, 2021, 6, 2305-2315.	0.8	26
30	Thrombotic thrombocytopenic purpura and acute renal failure in adult Still's disease. Nephrology Dialysis Transplantation, 1997, 12, 1471-1473.	0.7	25
31	Maintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a historical prospective study. Kidney International, 2008, 74, S82-S87.	5.2	21
32	Fracaso renal agudo en pacientes hospitalizados por COVID-19. Nefrologia, 2021, 41, 34-40.	0.4	21
33	Peritoneal Dialysis can be an Option for Dominant Polycystic Kidney Disease: An Observational Study. Peritoneal Dialysis International, 2015, 35, 530-536.	2.3	20
34	Residual Renal Function in Hemodialysis and Inflammation. Therapeutic Apheresis and Dialysis, 2017, 21, 592-598.	0.9	19
35	Previous comorbidity and lack of patient free choice of technique predict early mortality in peritoneal dialysis. Peritoneal Dialysis International, 2009, 29, 150-7.	2.3	17
36	Outcome of polycystic kidney disease patients on peritoneal dialysis: Systematic review of literature and meta-analysis. PLoS ONE, 2018, 13, e0196769.	2.5	16

#	ARTICLE	IF	CITATIONS
37	Risk Factors for Clostridium Difficile Diarrhea in Patients With Solid Organ Transplantation. Progress in Transplantation, 2016, 26, 231-237.	0.7	15
38	Acute kidney failure in patients admitted due to COVID-19. Nefrologia, 2021, 41, 34-40.	0.4	15
39	VISCERAL LEISHMANIASIS. Transplantation, 1994, 57, 1677.	1.0	15
40	Renal Magnesium Wasting with Hypercalciuria, Nephrocalcinosis and Ocular Disorders. Nephron, 1995, 69, 472-475.	1.8	14
41	Early outcomes of kidney transplantation from elderly donors after circulatory death (GEODAS) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.8	14
42	Hypomagnesemic Hypocalcemia in Chronic Renal Failure. American Journal of Kidney Diseases, 1993, 21, 167-171.	1.9	12
43	Course of Vascular Access and Relationship with Treatment of Anemia. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 1163-1169.	4.5	12
44	Characteristics, management and outcomes of atypical haemolytic uraemic syndrome in kidney transplant patients: a retrospective national study. CKJ: Clinical Kidney Journal, 2021, 14, 1173-1180.	2.9	12
45	Lymphocyte-depleting induction and steroid minimization after kidney transplantation: A review. Nefrologia, 2016, 36, 469-480.	0.4	11
46	Ferroterapia en el manejo de la anemia en la enfermedad renal crónica no en diálisis: perspectiva del grupo de anemia de la S.E.N. Nefrologia, 2021, 41, 123-136.	0.4	8
47	Una visión nefrológica del tratamiento sustitutivo renal en el paciente crónico con fracaso renal agudo: horizonte 2020. Nefrologia, 2021, 41, 102-114.	0.4	7
48	Recommendations for vaccination against pneumococcus in kidney patients in Spain. Nefrologia, 2014, 34, 545-51.	0.4	7
49	Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination. Frontiers in Immunology, 2022, 13, 845882.	4.8	6
50	Corticosteroids and mycophenolic acid analogues in immunoglobulin A nephropathy with progressive decline in kidney function. CKJ: Clinical Kidney Journal, 2022, 15, 771-777.	2.9	6
51	Impact of the COVID pandemic on vascular access creation for haemodialysis in 16 Spanish haemodialysis centres. CKJ: Clinical Kidney Journal, 2022, 15, 1340-1347.	2.9	6
52	Peritoneal dialysis and kidney transplant. A two-way ticket in an integrated renal replacement therapy model. Nefrologia, 2011, 31, 441-8.	0.4	6
53	Surgical treatment of juxta-anastomotic stenosis in radiocephalic fistula. A new proximal radiocephalic anastomosis. Nefrologia, 2012, 32, 517-22.	0.4	6
54	Abdominal Wall Leakage on CAPD: Usefulness of Ultrasonography. Nephron, 1995, 69, 348-349.	1.8	5

#	ARTICLE	IF	CITATIONS
55	Peritoneal Dialysis for Patients With Polycystic Kidney Disease in Spain. <i>American Journal of Kidney Diseases</i> , 2011, 58, 493.	1.9	5
56	Kidney Transplantation With Organs From Donors After Circulatory Death Type 3: A Prospective Multicentric Spanish Study (GEODAS 3). <i>Transplantation Proceedings</i> , 2015, 47, 27-29.	0.6	5
57	Impacto del primer año de tratamiento sustitutivo renal en la hospitalización de una comunidad autónoma. <i>Nefrología</i> , 2019, 39, 653-663.	0.4	5
58	Trasplante renal con órganos procedentes de donación tras parada circulatoria controlada: resultados del estudio multicéntrico GEODAS-3. <i>Nefrología</i> , 2019, 39, 151-159.	0.4	5
59	Anemia management and treatment response in patients on hemodialysis: the MAR study. <i>Journal of Nephrology</i> , 2006, 19, 352-60.	2.0	5
60	Exploring dosing frequency and administration routes in the treatment of anaemia in CKD patients. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, viii13-viii17.	0.7	4
61	¿Cómo debemos analizar y describir la mortalidad de nuestros pacientes: experiencia del Grupo Centro Diálisis Peritoneal. <i>Nefrología</i> , 2016, 36, 149-155.	0.4	4
62	Insuficiencia cardíaca en la enfermedad renal y déficit de hierro: importancia de la feroterapia. <i>Nefrología</i> , 2017, 37, 587-591.	0.4	4
63	Effectiveness and safety of ferric carboxymaltose therapy in peritoneal dialysis patients: an observational study. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 174-180.	2.9	4
64	Kidney Transplants in Controlled Donation Following Circulatory Death, or Maastricht Type III Donors, With Abdominal Normothermic Regional Perfusion, Optimizing Functional Outcomes. <i>Transplantation Direct</i> , 2021, 7, e725.	1.6	4
65	Use of radioactive iodine I-131 and monitoring of radioactivity in patients with chronic kidney disease on haemodialysis. <i>Nefrología</i> , 2014, 34, 317-22.	0.4	4
66	Activation of the Sympathetic Nervous System in Hemodialyzed Patients Treated with Erythropoietin. <i>Nephron</i> , 1995, 69, 350-350.	1.8	3
67	Suppression of Immune Parameters in Animal Models of Morphine Dependence. <i>Immunological Investigations</i> , 1995, 24, 643-652.	2.0	3
68	Functional renal recovery after spontaneous renal embolization in a sole kidney. <i>Nephrology Dialysis Transplantation</i> , 1997, 12, 2417-2419.	0.7	3
69	Anemia Development and Cardiovascular Risk Management in Nonanemic Stage 3 Chronic Kidney Disease. <i>Renal Failure</i> , 2009, 31, 869-875.	2.1	3
70	Cinacalcet Improves Control of Secondary Hyperparathyroidism in Peritoneal Dialysis: A Multicenter Study. <i>Peritoneal Dialysis International</i> , 2012, 32, 208-211.	2.3	3
71	Midterm Results of Renal Transplantation From Controlled Cardiac Death Donors Are Similar to Those From Brain Death Donors. <i>Transplantation Proceedings</i> , 2016, 48, 2862-2866.	0.6	3
72	Kidney Transplantation in Patients With Chronic Kidney Disease After a Previous Lung Transplantation. <i>Transplantation Proceedings</i> , 2019, 51, 324-327.	0.6	3

#	ARTICLE	IF	CITATIONS
73	First episodes of peritoneal infection: description and prognostic factors. <i>Nefrologia</i> , 2013, 33, 316-24.	0.4	3
74	Beneficial dose conversion after switching from higher doses of shorter-acting erythropoiesis-stimulating agents to C.E.R.A in CKD patients in clinical practice: MINERVA Study. <i>International Urology and Nephrology</i> , 2014, 46, 1983-1995.	1.4	2
75	Effect of balance Solution on the Peritoneal Membrane in Automated Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2016, 36, 569-572.	2.3	2
76	¿Es adecuada la diálisis peritoneal para pacientes mayores de 65 años? Estudio multicéntrico prospectivo. <i>Nefrologia</i> , 2021, 41, 529-538.	0.4	2
77	Effect of Expanded Hemodialysis with Theranova® in Patients with COVID-19. <i>Blood Purification</i> , 2022, 51, 857-865.	1.8	2
78	The hidden diabetic kidney disease in a university hospital-based population: a real-world data analysis. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1865-1871.	2.9	2
79	Early Outcomes and Risk Factors for Kidney Transplantation with Controlled Circulatory Death Donor (cDCD) in a Nationwide Strategy. Spanish Multicentre SENTRA-GEODAS-Group. <i>Transplantation</i> , 2018, 102, S32-S33.	1.0	1
80	Impact of first year renal replacement therapy on the hospital admissions of a regional public health system. <i>Nefrologia</i> , 2019, 39, 653-663.	0.4	1
81	Non-valvular Atrial Fibrillation in CKD: Role of Vitamin K Antagonists and Direct Oral Anticoagulants. A Narrative Review. <i>Frontiers in Medicine</i> , 2021, 8, 654620.	2.6	1
82	Geographical variability of patient characteristics and treatment patterns affect outcomes for incident hemodialysis patients. <i>Journal of Nephrology</i> , 2013, 26, 119-128.	2.0	1
83	Is peritoneal dialysis suitable technique CKD patients over 65 years? A prospective multicenter study. <i>Nefrologia</i> , 2021, 41, 529-538.	0.4	1
84	About "Low Mortality and Key Aspects of Delivery of Care for End-Stage Renal Disease in Italy" Scientific World Journal, The, 2009, 9, 360-362.	2.1	0
85	Nefropatía IgA asociada a nefritis intersticial aguda tras administración de contraste yodado. <i>Nefrologia</i> , 2015, 35, 582-584.	0.4	0
86	IgA nephropathy associated with acute interstitial nephritis after administering iodinated contrast media. <i>Nefrologia</i> , 2015, 35, 582-584.	0.4	0
87	FP849 KIDNEY TRANSPLANTATION WITH ORGANS FROM CONTROLLED DONORS AFTER CIRCULATORY DEATH: EARLY REPORT FROM SPANISH MULTICENTRE EXPERIENCE. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii361-iii361.	0.7	0
88	FP595 ON THE VIEW OF CLINICAL OUTCOMES, SHOULD WE OFFER PD FOR ELDERLY PATIENTS?. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii271-iii271.	0.7	0
89	How should we analyze and present mortality in our patients?: a multicentre GCDP experience. <i>Nefrologia</i> , 2016, 36, 149-155.	0.4	0
90	Debemos evaluar el daño renal previo en el fracaso renal agudo por COVID-19. <i>Nefrologia</i> , 2021, , .	0.4	0

#	ARTICLE	IF	CITATIONS
91	Análisis de las transiciones en el modelo integrado de tratamiento sustitutivo renal en un sistema regional de salud. Nefrologia, 2022, 42, 438-447.	0.4	0
92	Apoyo enfermero de una unidad de diálisis en el desarrollo de un programa de trasplante renal con Órganos procedentes de donación tras asistolia controlada, tipo III de Maastricht. Enfermeria Nefrologica, 0, 16, 166-167.	0.3	0
93	Risk Factors for Clostridioides Difficile Diarrhea In Solid Organ Transplantation Recipients. Transplantation Proceedings, 2021, 53, 2826-2832.	0.6	0
94	Implementation of clinical guidelines and compliance with target haemoglobin levels in peritoneal dialysis. Nefrologia, 2013, 33, 140-2.	0.4	0
95	Comment on "Magnesium and chronic kidney disease". Nefrologia, 2013, 33, 849-50.	0.4	0